Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
Cephalalgia
; 29 Suppl 2: 7-16, 2009 Nov.
Article
de En
| MEDLINE
| ID: mdl-19723121
ABSTRACT
The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Benzamides
/
Benzopyranes
/
Analgésiques
/
Migraines
Type d'étude:
Clinical_trials
Limites:
Adult
/
Female
/
Humans
/
Male
Langue:
En
Journal:
Cephalalgia
Année:
2009
Type de document:
Article
Pays d'affiliation:
Suède